EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Amide proton transfer-weighted (APTw) CEST MRI in clinical routine for single time point diagnosis of pseudoprogression in IDH-wildtype glioblastoma

Thomas Zeyen iD, Inga Krause, Andreas Decker, Florian Kroh, Sebastian Regnery, Johannes Weller iD, Niklas Schaefer, Mousa Zidan, Anna-Laura Potthoff iD, Matthias Schneider iD, Lea L Friker, Jochen Keupp und 9 weitere

Neuro-Oncology · 01.03.2026 · 28 (3) · 790-801

DOI: 10.1093/neuonc/noaf261 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuro-Oncology, online erschienen am 13.11.2025. Verfasst von Thomas Zeyen und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurooncology, Centers for Neurology and Integrated Oncology (CIO), University Hospital Bonn, Bonn, Germany (T.Z., J.W., N.S., C.S., U.…. Hauptthemen laut MEDLINE: Glioblastoma, Brain Neoplasms, Magnetic Resonance Imaging, Isocitrate Dehydrogenase. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical -Faculty, University of Bonn, Else Kroener Fresenius Stiftung.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Differentiating progressive disease (PD) from treatment-related effects (TRE) in glioblastoma remains challenging, particularly at single time point evaluations. TRE can occur at any disease stage, and its underlying biology is poorly understood. This study evaluates the clinical feasibility and diagnostic performance of amide proton transfer-weighted (APTw) MRI in this challenge.

Methods

Following the integration of APTw MRI into the routine clinical workflow for brain tumor imaging, we screened a total of 870 scans from 626 patients. APTw signal (voxel-based measurement) was automatically quantified in gadolinium-enhanced T1w and FLAIR regions of interest using a deep learning-based approach for 3D tumor segmentations. PD and TRE were compared using unpaired t-tests, and diagnostic accuracy was assessed via ROC- and logistic regression analysis.

Results

Among 256 MRI scans of 143 patients with glioblastoma, 65 scans showed PD (n = 42) or TRE (n = 23). The median APTw signal was higher in PD (2.23%) vs TRE (1.67%; P = .0001). ROC analysis showed an area under the curve (AUC) of 0.82. In patients with early PD or TRE (<6 months post-radiotherapy), the AUC increased to 0.93. Anti-angiogenic therapy decreased APTw signal (P < .01). Combining APTw MRI with DWI and PWI improved diagnostic accuracy (AUC = 0.90).

Conclusions

APTw MRI is a non-invasive imaging tool that is feasible for clinical routine and aids in differentiation of early progression from pseudoprogression in glioblastoma. Its diagnostic accuracy decreases with application of anti-angiogenic treatment and at later follow-up time points. Highest diagnostic accuracy was found in a multimodal approach combining APTw MRI, PWI and DWI.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaBrain NeoplasmsMagnetic Resonance ImagingIsocitrate DehydrogenaseHumansFemaleMaleMiddle AgedDisease ProgressionAgedAdultPrognosisAmidesFollow-Up StudiesProtons

Stichwörter der Autor:innen

APTw MRICESTDWIamide proton transfer-weighted imagingbiomarkerschemical exchange saturation transferglioblastomaperfusionpseudoprogression

Substanzen

Isocitrate DehydrogenaseAmidesProtons

Autor:innen und Institutionen

  • Department of Neurooncology, Centers for Neurology and Integrated Oncology (CIO), University Hospital Bonn, Bonn, Germany (T.Z., J.W., N.S., C.S., U.H.).
  • Department of Radiology, Brigham and Womeńs Hospital, Harvard Medical School, Boston, Massachusetts (T.Z., I.K., F.K., D.P.).
  • Department of Neuroradiology, University Hospital Bonn, Bonn, Germany (I.K., M.Z., A.R., D.P.).
  • German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany (A.D.).
  • Department of Radiation Oncology, University Hospital Heidelberg, Heidelberg, Germany (S.R.).
  • Department of Vascular Neurology, Center for Neurology, University Hospital Bonn, Bonn, Germany (J.W.).

ORCID-Profile: Thomas Zeyen, Johannes Weller, Anna-Laura Potthoff, Matthias Schneider, Daniel Paech

Förderung

  • Medical -Faculty
  • University of Bonn
  • Else Kroener Fresenius Stiftung
  • Medical Faculty of the University of Bonn
  • German Research Foundation
  • Medical ­Faculty

Zitieren

APA

Zeyen, T., Krause, I., Decker, A., Kroh, F., Regnery, S., Weller, J., Schaefer, N., Zidan, M., Potthoff, A. L., Schneider, M., Friker, L. L., Keupp, J., Katemann, C., Layer, J. P., Schaub, C., Gkika, E., Vatter, H., Pietsch, T., Radbruch, A., …, & Paech, D. (2026). Amide proton transfer-weighted (APTw) CEST MRI in clinical routine for single time point diagnosis of pseudoprogression in IDH-wildtype glioblastoma. Neuro-Oncology, 28(3), 790-801. https://doi.org/10.1093/neuonc/noaf261

Vancouver

Zeyen T, Krause I, Decker A, Kroh F, Regnery S, Weller J, et al. Amide proton transfer-weighted (APTw) CEST MRI in clinical routine for single time point diagnosis of pseudoprogression in IDH-wildtype glioblastoma. Neuro-Oncology. 2026;28(3):790-801. doi:10.1093/neuonc/noaf261

BibTeX
@article{Zeyen2026,
  author = {Zeyen, Thomas and Krause, Inga and Decker, Andreas and Kroh, Florian and Regnery, Sebastian and Weller, Johannes and Schaefer, Niklas and Zidan, Mousa and Potthoff, Anna-Laura and Schneider, Matthias and Friker, Lea L and Keupp, Jochen and Katemann, Christoph and Layer, Julian P and Schaub, Christina and Gkika, Eleni and Vatter, Hartmut and Pietsch, Torsten and Radbruch, Alexander and Herrlinger, Ulrich and Paech, Daniel},
  title = {Amide proton transfer-weighted (APTw) CEST MRI in clinical routine for single time point diagnosis of pseudoprogression in IDH-wildtype glioblastoma},
  journal = {Neuro-Oncology},
  year = {2026},
  volume = {28},
  number = {3},
  pages = {790--801},
  doi = {10.1093/neuonc/noaf261}
}
Kostenlos starten →